Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

NCT04108962 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Difficult to find eligible patients willing to participate.

Conditions

ABPA
Severe Asthma
Allergic Bronchopulmonary Aspergillosis

Interventions

DRUG: Fasenra, 30 Mg/mL Subcutaneous Solution

Sponsor

Baylor Research Institute